Clinical Trial Update: IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of IPI-Biotherapy for metastatic melanoma in patients previously treated with cytotoxic chemotherapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 1, Phase 2 | Status: WITHDRAWN